ClinicalImpact™ RET-Altered or RET-Driven NSCLC and Thyroid Cancer: Expert Guidance for Improving Outcomes

Using a recent patient case from my practice, I describe how I am incorporating new selective RET inhibitors such as selpercatinib into managing patients with RET fusion–positive NSCLC.

Karen L. Reckamp, MD, MS Released: September 2, 2020

My take on how selective RET inhibitors are changing the standard of care in advanced thyroid cancer.

Lori J. Wirth, MD Released: November 4, 2020

Here are my thoughts on what patients need to know about biomarker testing and targeted therapies for lung and thyroid cancers.

Marianne Davies, DNP, CNS, ACNP-BC, AOCNP Released: February 23, 2021

Read expert answers to key questions asked by healthcare professionals during a series of live webinars focused on the optimal use of selective RET inhibitors in the treatment of advanced cancers with RET alterations, including how to differentiate between these agents and what to do after progression on them.

Joshua Bauml, MD Released: May 11, 2021